With just 6 doses a year, following initiation,[1,2] when compared to regular daily orals, VOCABRIA+ REKAMBYS offers people living with HIV the opportunity to thrive through:
Learn more about the efficacy and effectiveness of VOCABRIA + REKAMBYS and how it could benefit people living with HIV like Gabriel
VOCABRIA + REKAMBYS could benefit more people living with HIV than you realise
VOCABRIA + REKAMBYS has been studied in broad and diverse populations of people living with HIV[12]
Gabriel, 24
Early in his treatment journey and wants a treatment that fits his lifestyle
Will, 56
Wants to minimise the impact managing HIV has on his health as he ages
Karen, 57
Doesn’t want to forget to take her tablets, like she does with her other non-HIV pills
Adrian, 38
Wants to travel without worrying about someone finding his pills
More people living with HIV would be interested in trying long-acting injectable ART than many physicians might assume[13]
All people living with HIV pictured on this website have been prescribed every-2-month VOCABRIA + REKAMBYS, and all healthcare professionals pictured in this material are paid actors. They have given their consent for the use of their images and have received remuneration from ViiV Healthcare.
Indication: VOCABRIA injection is indicated, in combination with REKAMBYS injection, for the treatment of HIV-1 infection in adults and adolescents (at least 12 years of age and weighing at least 35 kg), who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class.[1,2]
ART=antiretroviral therapy; HIV=human immunodeficiency virus; HIV-1=human immunodeficiency virus type 1; INI=integrase inhibitor; NNRTI=non-nucleoside reverse transcriptase inhibitor; RNA=ribonucleic acid.
References:
- VOCABRIA (cabotegravir) 600 mg suspension for injection Summary of Product Characteristics(SmPC).
- REKAMBYS (rilpivirine) 900 mg suspension for injection Summary of Product Characteristics (SmPC).
- Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):e566–e577. doi: 10.1016/S2352-3018(23)00136-4.
- Kityo C, Mambule IK, Musaazi J. et al. Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial. Nat Med. 2025. https://doi.org/10.1038/s41591-025-04041-7
- Sension M, Hsu RK, Fusco JS, et al. Few differences in persistence and virologic outcomes across age groups among CAB+RPV LA users: Findings from the OPERA Cohort. Presented at: ID Week; October 19-22, 2025; Atlanta, Georgia, USA. Poster P-371.
- Pozniak A, Sridhar G, Assoumou L, et al. High Virologic Suppression and few Virologic Failures with Long-Acting Cabotegravir + Rilpivirine in Treatment Experienced Virologically Suppressed Individuals from COMBINE-2 cohort in Europe. Presented at: The 13th International AIDS Society (IAS) Conference; July 13–17, 2025; Kigali, Rwanda. Poster EP0171.
- Buzón-Martín L, Montes ML, Galindo Puerto MJ, et al. A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study). J Antimicrob Chemother. 2025. doi:10.1093/jac/dkaf389.
- Wyen C, Noe S, Jonsson-Oldenbüttel C, et al. 24-Month Outcomes of Cabotegravir Plus Rilpivirine Long-Acting Every 2 Months in a Real-World Setting: Effectiveness, Adherence to Injections, and Patient-Reported Outcomes From People With HIV-1 in the German CARLOS Study. Presented at: The 13th International AIDS Society (IAS) Conference; July 13–17, 2025; Kigali, Rwanda. Poster TUPEB035.
- Muccini C, Capra N, Lolatto R, et al. Two-years efficacy and safety of long-acting cabotegravir and rilpivirine in the SCohoLART study. Presented at: The Italian Conference on AIDS and Antiviral Research (ICAR); May 21–23, 2025; Padua, Italy. Oral presentation OC35.
- John M, Williams L, Nolan G, et al. Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS). HIV Med. 2024;25(8):935–945. doi: 10.1111/hiv.13647.
- Brogan AP, Holbrook T, Hennessy F, et al. People With HIV in the United States (US) Switching to Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) From Oral Antiretroviral Therapy (ART) Have Numerous Real-World Benefits, Including High Adherence and Treatment Satisfaction. Presented at: ID Week; October 16–19, 2024. Los Angeles, California, USA. Poster 538.
- Data on File. Number of people with HIV that have received VOCABRIA + REKAMBYS in clinical trials and real-world studies. June 2025. REF-280327. ViiV Healthcare group of companies.
- Moreno C, Izquierdo R, Alejos B, et al. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain. AIDS Patient Care STDS. 2024;38(7):305–314. doi: 10.1089/apc.2024.0093.
REKAMBYS (rilpivirine long-acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned or licensed by the ViiV Healthcare group. ©2025 ViiV Healthcare group of companies or its licensor. All rights reserved.
PM-GB-CBR-WCNT-250006 | March 2026
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.
